{"title":"The effect of misclassification on sample size for one and two-sample tests with binary endpoints.","authors":"Péter Hársfalvi, Jenő Reiczigel","doi":"10.1080/10543406.2024.2444231","DOIUrl":null,"url":null,"abstract":"<p><p>In recent years, an increasing number of publications on the analysis of binary data have applied methods that take misclassification into account. However, potential misclassification is often ignored in study design due to the lack of sample size formulas or software. This may lead to a considerable loss of power in studies that only account for misclassification at the analysis stage. We argue that analyses correcting for misclassification should be used in combination with appropriate sample size adjustment in the design phase of the studies. We illustrate the importance of this by comparing the required sample sizes with and without misclassification, and provide an appropriate sample size procedure implemented as an R function for the one-sample and two-sample tests for binary endpoints. The sample size is calculated from the presumed binomial parameters (<i>p</i><sub>0</sub> and <i>p</i><sub><i>a</i></sub> for one-sample and <i>p</i><sub>1</sub> and <i>p</i><sub>2</sub> for two-sample tests), the required power, and the probabilities of correct classification, sensitivity (<i>Se)</i>, and specificity (<i>Sp)</i>. Our results show that misclassification may drastically affect the necessary sample size in both testing scenarios.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-12"},"PeriodicalIF":1.2000,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2024.2444231","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
In recent years, an increasing number of publications on the analysis of binary data have applied methods that take misclassification into account. However, potential misclassification is often ignored in study design due to the lack of sample size formulas or software. This may lead to a considerable loss of power in studies that only account for misclassification at the analysis stage. We argue that analyses correcting for misclassification should be used in combination with appropriate sample size adjustment in the design phase of the studies. We illustrate the importance of this by comparing the required sample sizes with and without misclassification, and provide an appropriate sample size procedure implemented as an R function for the one-sample and two-sample tests for binary endpoints. The sample size is calculated from the presumed binomial parameters (p0 and pa for one-sample and p1 and p2 for two-sample tests), the required power, and the probabilities of correct classification, sensitivity (Se), and specificity (Sp). Our results show that misclassification may drastically affect the necessary sample size in both testing scenarios.
期刊介绍:
The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers:
Drug, device, and biological research and development;
Drug screening and drug design;
Assessment of pharmacological activity;
Pharmaceutical formulation and scale-up;
Preclinical safety assessment;
Bioavailability, bioequivalence, and pharmacokinetics;
Phase, I, II, and III clinical development including complex innovative designs;
Premarket approval assessment of clinical safety;
Postmarketing surveillance;
Big data and artificial intelligence and applications.